Emerging Tests for Noninvasive Colorectal Cancer Screening
Clinical Gastroenterology and Hepatology · 2023-03 · 21 (3) · 604-616
DOI: 10.1016/j.cgh.2022.12.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-03. Verfasst von Marina Hanna und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington, Seattle, Washington. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute Division of Cancer Prevention.
Abstract (Originalsprache)
Colorectal cancer (CRC) is among the most common cancers globally and a major cause of cancer-related deaths. The American Cancer Society estimates that CRC will kill 1 in 60 Americans, and CRC screening is recommended for all Americans ≥45 years of age. Current CRC screening methods are effective for preventing CRC and have been shown to reduce CRC-related mortality. However, none of the currently available tests is ideal, and many people are not compliant with screening recommendations. Novel screening tests based on advances in CRC molecular biology, genetics, and epigenetics, combined with developments in sequencing technologies and computational analytic methods, have been developed to address the shortcomings of current CRC screening tests. These emerging tests include blood-based assays that use plasma-derived circulating tumor DNA and serum proteins to detect early CRC and advanced adenomas, assays that use stool DNA or mRNA, and methods for profiling the gut microbiome. Here we review current screening modalities, and we discuss the principles behind the most promising emerging CRC screening tests and the data supporting their potential to be used in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Washington, Seattle, Washington.
- Department of Medicine, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Microbiome Research Initiative, Fred Hutchinson Cancer Center, Seatt…
- Department of Medicine, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. Electronic address: wgrady@fredhutch.org.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute Division of Cancer Prevention
Zitieren
APA
Hanna, M., Dey, N., & Grady, W. M. (2023). Emerging Tests for Noninvasive Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 21(3), 604-616. https://doi.org/10.1016/j.cgh.2022.12.008
Vancouver
Hanna M, Dey N, Grady WM. Emerging Tests for Noninvasive Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology. 2023;21(3):604-616. doi:10.1016/j.cgh.2022.12.008
BibTeX
@article{Hanna2023,
author = {Hanna, Marina and Dey, Neelendu and Grady, William M},
title = {Emerging Tests for Noninvasive Colorectal Cancer Screening},
journal = {Clinical Gastroenterology and Hepatology},
year = {2023},
volume = {21},
number = {3},
pages = {604--616},
doi = {10.1016/j.cgh.2022.12.008}
}
EUVIMED